Taylor Morrisette1,2, Matthew A Miller2, Brian T Montague3,4, Gerard R Barber2, R Brett McQueen5, Martin Krsak3,4. 1. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. 2. Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Aurora, CO, USA. 3. Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA. 4. Department of Medicine, University of Colorado Hospital, Aurora, CO, USA. 5. Department of Pharmaceutical Outcomes Research, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
Abstract
BACKGROUND: Long-acting lipoglycopeptides (laLGPs) are FDA approved only for acute bacterial skin and skin structure infections (ABSSSIs). However, these antibiotics show promise for off-label use, reductions in hospital length of stay (LOS) and healthcare cost savings. OBJECTIVES: To assess the effectiveness, safety, impact on LOS and estimated cost savings from laLGP treatment for Gram-positive infections. METHODS: Retrospective cohort of adult patients who received at least one dose of laLGPs at the University of Colorado Health system. Descriptive statistics were utilized for analysis. RESULTS: Of 59 patients screened, 56 were included: mean age 47 years, 59% male and 30% injection drug users/polysubstance abusers (dalbavancin, 71%; oritavancin, 25%; both, 4%). Most common indications for laLGP: ABSSSIs (36%), osteomyelitis (27%) and endocarditis (9%). Most common isolated pathogens: MSSA and MRSA (25% and 19%, respectively), Enterococcus faecalis (11%) and CoNS (11%). Previous antibiotics were administered for a median of 13 days (IQR = 7.0-24.5 days) and laLGPs for a median of one dose (IQR = 1-2 doses). Ten (18%) patients were lost to follow-up. Clinical failure was found in 7/47 (15%) cases with adequate follow-up. Mild adverse effects occurred in six (11%) patients. Projected reduction in hospital LOS and health-system costs were 514 days (9.18 days/person average) and $963456.72 ($17204.58/person average), respectively. CONCLUSIONS: Prospective trials are needed to validate the use of these antibiotics for Gram-positive infections in practice, with the hope that they will reduce hospital LOS and the need for daily antibiotic infusions to provide alternative options for patients not qualifying for outpatient parenteral antimicrobial therapy.
BACKGROUND: Long-acting lipoglycopeptides (laLGPs) are FDA approved only for acute bacterial skin and skin structure infections (ABSSSIs). However, these antibiotics show promise for off-label use, reductions in hospital length of stay (LOS) and healthcare cost savings. OBJECTIVES: To assess the effectiveness, safety, impact on LOS and estimated cost savings from laLGP treatment for Gram-positive infections. METHODS: Retrospective cohort of adult patients who received at least one dose of laLGPs at the University of Colorado Health system. Descriptive statistics were utilized for analysis. RESULTS: Of 59 patients screened, 56 were included: mean age 47 years, 59% male and 30% injection drug users/polysubstance abusers (dalbavancin, 71%; oritavancin, 25%; both, 4%). Most common indications for laLGP: ABSSSIs (36%), osteomyelitis (27%) and endocarditis (9%). Most common isolated pathogens: MSSA and MRSA (25% and 19%, respectively), Enterococcus faecalis (11%) and CoNS (11%). Previous antibiotics were administered for a median of 13 days (IQR = 7.0-24.5 days) and laLGPs for a median of one dose (IQR = 1-2 doses). Ten (18%) patients were lost to follow-up. Clinical failure was found in 7/47 (15%) cases with adequate follow-up. Mild adverse effects occurred in six (11%) patients. Projected reduction in hospital LOS and health-system costs were 514 days (9.18 days/person average) and $963456.72 ($17204.58/person average), respectively. CONCLUSIONS: Prospective trials are needed to validate the use of these antibiotics for Gram-positive infections in practice, with the hope that they will reduce hospital LOS and the need for daily antibiotic infusions to provide alternative options for patients not qualifying for outpatient parenteral antimicrobial therapy.
Authors: Kyle C Molina; Matthew A Miller; Scott W Mueller; Edward T Van Matre; Martin Krsak; Tyree H Kiser Journal: Clin Pharmacokinet Date: 2021-12-21 Impact factor: 5.577
Authors: Taylor Morrisette; Matthew A Miller; Brian T Montague; Gerard R Barber; R Brett McQueen; Martin Krsak Journal: Open Forum Infect Dis Date: 2019-06-05 Impact factor: 3.835
Authors: Katherine Taylor; John Williamson; Vera Luther; Tyler Stone; James Johnson; Zachary Gruss; Courtney Russ-Friedman; Chris Ohl; James Beardsley Journal: Infect Dis Rep Date: 2022-04-11
Authors: Kyle C Molina; Cali Lunowa; Madelyn Lebin; Andrea Segerstrom Nunez; Sara F Azimi; Martin Krsak; Scott W Mueller; Matthew A Miller Journal: Open Forum Infect Dis Date: 2022-07-14 Impact factor: 4.423
Authors: Carmen Hidalgo-Tenorio; David Vinuesa; Antonio Plata; Pilar Martin Dávila; Simona Iftimie; Sergio Sequera; Belén Loeches; Luis Eduardo Lopez-Cortés; Mari Carmen Fariñas; Concepción Fernández-Roldan; Rosario Javier-Martinez; Patricia Muñoz; Maria Del Mar Arenas-Miras; Francisco Javier Martínez-Marcos; Jose Maria Miró; Carmen Herrero; Elena Bereciartua; Samantha E De Jesus; Juan Pasquau Journal: Ann Clin Microbiol Antimicrob Date: 2019-10-19 Impact factor: 3.944
Authors: Laura Herrera-Hidalgo; Rafael Luque-Márquez; Aristides de Alarcon; Ana Belén Guisado-Gil; Belen Gutierrez-Gutierrez; Maria Dolores Navarro-Amuedo; Julia Praena-Segovia; Juan Manuel Carmona-Caballero; Elena Fraile-Ramos; Alicia Gutierrez-Valencia; Luis Eduardo Lopez-Cortes; Maria Victoria Gil-Navarro Journal: J Clin Med Date: 2022-03-11 Impact factor: 4.241